Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma

Pancreas

Volumn 41, Issue 3, 2012, Pages 416-421

  Handra Luca, Adriana ^a,b   Lesty, Claude ^c   Hammel, Pascal ^d,e   Sauvanet, Alain ^d,e   Rebours, Vinciane ^d,e   Martin, Antoine ^b,f   Fagard, Remi ^b,f   Fléjou, Jean François ^g,h   Faivre, Sandrine ^d,e,i   Bédossa, Pierre ^d,e,i   Ruszniewski, Philippe ^d,e,i   Couvelard, Anne ^d,e,i  

^a APHP Groupe Hospitalier Universitaire Nord   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f AVICENNE HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

adenocarcinoma; MAPK; pancreas; prognosis; proliferation; signaling pathway

Indexed keywords

KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MAP KINASE KINASE 4; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATECTOMY; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859104993     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318238379d     Document Type: Article

References (39)

1. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26:3511-3516.
2. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503-3510.
3. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008;37:352-357.
4. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005;128:1642-1654. (Pubitemid 40692557)
5. Casneuf VF, Fonteyne P, Van Damme N, et al. Expression of sGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest. 2008;26:852-859.
6. Hirata K, Sato T, Mukaiya M, et al. Results of1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg. 1997;132:771-776. (Pubitemid 27305232)
7. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vsgemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026. (Pubitemid 351347058)
8. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928-3935.
9. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
10. Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol. 2008;15:2773-2786.
11. Neuhaus P, Riess H, Post S, et al. Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resectable pancreatic cancer. J Clin Oncol. 2008;26:A4504.
12. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073-1081.
13. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310. (Pubitemid 46763022)
14. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947. (Pubitemid 39626217)
15. Ji Z, Mei FC, Xie J, et al. Oncogenic KRAS activates hedgehog signalling pathway in pancreatic cancer cells. J Biol Chem. 2007;282:14048-14055. (Pubitemid 47100411)
16. Pham NA, Schwock J, Iakovlev V, et al. Immunohistochemical analysis of changes in signalling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 2008;8:43. (Pubitemid 351454858)
17. Chadha KS, Khoury T, Yu J, Black JD, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006;13:933-939.
18. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14:3527-3533. (Pubitemid 350160113)
19. Liang JJ, Wang H, Rashid A, et al. Expression of mAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14:7043-7049.
20. Hruban RH, Boffetta P, Hiraoka N, et al. Ductal adenocarcinoma of the pancreas. In: Bosman F, Carneiro F, Hruban H, Theise N, eds. WHO Classification of Digestive Tumours. 4th ed. Lyon, France: IARC Press; 2010:281-290.
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:241-251.
22. Cascinu S, Jelic S. Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:iv37-iv40.
23. Yeo CJ, Yeo TP, Hruban RH, et al. Cancer of the pancreas. In: DeVita VR, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:945-985.
24. Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005;46:668-676. (Pubitemid 40834826)
25. Couvelard A, Hu J, Steers G, et al. Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology. 2006;131:1597-1610. (Pubitemid 44780863)
26. Handra-Luca A, Bilal H, Bertrand JC, et al. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumour behavior and tumour cell proliferation. Am J Pathol. 2003;163:957-967. (Pubitemid 37040131)
27. Handra-Luca A, Mauguen A, Menard P, et al. Coordinated expression of activated mitogen-activated protein kinases in salivary gland adenoid cystic carcinoma. Hum Pathol. 2008;39:1590-1596.
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000.
29. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;15:2846-2850. (Pubitemid 38509164)
30. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739-746.
31. Esteva FJ, Sahin AA, Smith TL, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004;100:499-506. (Pubitemid 38124766)
32. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signalling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A. 2003;100:7259-7264. (Pubitemid 36706426)
33. Demuth T, Reavie LB, Rennert JL, et al. MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther. 2007;6:1212-1222. (Pubitemid 46711984)
34. Wagner EF, Nebreda AR. Signal integration byJNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537-549.
35. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279-3290. (Pubitemid 46763021)
36. Xia D, Srinivas H, Ahn YH, et al. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem. 2007;282:3507-3519. (Pubitemid 47084470)
37. Xin W, Yun KJ, Ricci F, et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004;10:8516-8520. (Pubitemid 40053418)
38. Wang L, Pan Y, Dai JL. Evidence of mKK4 pro-oncogenic activity in breast and pancreatic tumours. Oncogene. 2004;23:5978-5985. (Pubitemid 39093542)
39. Ding XZ, Adrian TE. MEK/ERK-mediated proliferation isnegatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochem Biophys Res Commun. 2001;282:447-453. (Pubitemid 32917891)